Literature DB >> 9421798

Antiphospholipid antibodies and reproduction.

W H Kutteh1.   

Abstract

The antiphospholipid antibodies (APA) are acquired antibodies against a phospholipid which has been associated with slow progressive thrombosis and infarction in the placenta. Clinical features (venous or arterial thrombosis, recurrent fetal loss, thrombocytopenia) in conjunction with positive laboratory findings (positive IgG or IgM anticardiolipin antibodies, or positive lupus anticoagulant tests) will satisfy criteria for diagnosis of the antiphospholipid antibody syndrome (APS). A number of studies report the incidence of antiphospholipid antibodies in different patient populations: normal obstetrical patients (5.3% of 7278 women), women with recurrent pregnancy loss (20% of 2226 women), women with systemic lupus erythematosus (37% of 1579 women) and, more recently, women undergoing in vitro fertilization (24% of 3343 women). As in all autoimmune syndromes it is possible that APA are secondary to some underlying disease or that they are instrumental in the pathogenesis of the various manifestations. The most commonly proposed mechanisms of antiphospholipid antibody induced thrombosis include decreased prostacycline production by endothelial cells, increased thromboxane production by platelets, and decreased protein C activation. More recently it has been demonstrated that certain phospholipids are exposed on the endothelial surface and may alter implantation during in vitro fertilization. Treatment with subcutaneous heparin and aspirin has been shown to benefit women with recurrent pregnancy loss and APA resulting in successfully deliveries of approximately 75%. Several trials of treatment with heparin and aspirin in women with positive APA undergoing IVF have been completed. Although none of the studies were randomized, prospective, blinded trials there does not appear to be a significant difference in implantation rate, pregnancy rate, or ongoing pregnancy rate. This subject remains, however, an area of active investigation as antiphospholipid antibodies have been shown to interact with syncytiotrophoblast and cytotrophoblast layers and could theoretically affect implantation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9421798     DOI: 10.1016/s0165-0378(97)00059-4

Source DB:  PubMed          Journal:  J Reprod Immunol        ISSN: 0165-0378            Impact factor:   4.054


  3 in total

1.  Successful pregnancy after rituximab in a women with recurrent in vitro fertilisation failures and anti-phospholipid antibody positive.

Authors:  C T Ng; M O'Neil; D Walsh; T Walsh; D J Veale
Journal:  Ir J Med Sci       Date:  2009-12       Impact factor: 1.568

2.  Impact of presence of antiphospholipid antibodies on in vitro fertilization outcome.

Authors:  Yeon Hee Hong; Se Jeong Kim; Kyoung Yong Moon; Seul Ki Kim; Byung Chul Jee; Won Don Lee; Seok Hyun Kim
Journal:  Obstet Gynecol Sci       Date:  2018-05-08

Review 3.  Obstetrical antiphospholipid syndrome: from the pathogenesis to the clinical and therapeutic implications.

Authors:  T Marchetti; M Cohen; P de Moerloose
Journal:  Clin Dev Immunol       Date:  2013-07-30
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.